Dose Escalation of IPI-493 in Hematologic Malignancies

Infinity Pharmaceuticals

Status and phase: Terminated; Phase 1

Conditions: Hematologic Malignancies

Treatments: Drug: IPI-493

Study type: Interventional

Funder types: Industry

Identifiers

NCT01193491

IPI-493-02

Details and patient eligibility

About

The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.

Enrollment: 4 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• >/=18 years old
• ECOG 0-1
• confirmed hematological malignancy
• refractory to available therapy or for which no therapy is available
• adequate hepatic, renal function

Exclusion criteria

• active CNS malignancy
• prolonged QT interval
• significant GI/liver disease
• other serious concurrent illness or medical condition

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

4 participants in 1 patient group

IPI-493

Experimental group

Treatment:

Drug: IPI-493